Overview

A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors

Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
Phase:
Phase 1
Details
Lead Sponsor:
ImmunoGen, Inc.
Treatments:
Antibodies